Vivesto

0.239

SEK

-2.85 %

Less than 1K followers

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

-2.85%

+2.36%

-17.59%

-8.95%

-4.97%

-24.13%

-85.22%

-96.88%

-98.68%

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious diseases in oncology. The company researches new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1999 and is headquartered in Uppsala, Sweden.

Market cap

128.59M SEK

Turnover

107.84K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

8.5

2025

General meeting '25

8.5

2025

Interim report Q1'25

12.8

2025

Interim report Q2'25

ShowingAll content types

Press release2/20/2025, 4:10 PM

Carnegie Access: Vivesto: Intervju – Statusuppdatering efter Q4 2024-rapporten

Press release1/16/2025, 1:00 PM

Vivesto receives approval to initiate a dose-finding study of Paccal Vet in cats

Press release12/19/2024, 10:00 AM

Vivesto strengthens Cantrixil program with new preclinical results and patent application

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/11/2024, 10:33 AM

Vivesto’s Paccal Vet receives Limited Market classification in EU

Regulatory press release11/7/2024, 9:54 AM

Vivesto signs Apealea option agreement with Zhida Pharmaceutical

Press release7/1/2024, 6:00 AM

Vivesto receives positive Cantrixil preclinical efficacy data

Regulatory press release5/23/2024, 8:48 AM

Report from Annual General Meeting in Vivesto AB

Regulatory press release4/23/2024, 6:00 AM

Notice of Annual General Meeting in Vivesto AB

Press release3/19/2024, 12:06 PM

Vivesto to hold live-streamed Paccal Vet R&D Update on March 26

Regulatory press release3/7/2024, 7:10 AM

Vivesto doses first patient in its clinical Paccal Vet trial

Press release1/30/2024, 7:00 AM

Vivesto's international patent application for XR-18 receives positive decision

Press release12/28/2023, 7:00 AM

Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment

Regulatory press release12/22/2023, 4:26 PM

Vivesto’s Paccal Vet granted FDA MUMS designation

Regulatory press release12/22/2023, 3:28 PM

Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea

Press release12/19/2023, 11:28 AM

Vivesto reports positive preclinical data supporting continued development of Cantrixil

Regulatory press release11/23/2023, 8:11 PM

Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto

Regulatory press release11/23/2023, 6:30 AM

Vivesto and Elevar sign agreement ending Apealea® partnership

Regulatory press release11/16/2023, 7:00 AM

Interim report for the period January 1, 2023 – September 30, 2023

Regulatory press release10/25/2023, 5:30 AM

Vivesto focuses its project portfolio and introduces cost-saving measures

Regulatory press release9/15/2023, 7:19 PM

Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.